 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| 12» |
- | selisistat (SEN-196) / AOP Orphan Pharma
Preclinical, Journal: Activation of ALDH2 alleviates hypoxic pulmonary hypertension in mice by upregulating the SIRT1/PGC-1? signaling pathway (Pubmed Central) - Nov 16, 2024
ALDH2 alleviates hypoxiainduced senescence of pulmonary artery smooth muscle cells by upregulating the SIRT1/PGC-1? signaling pathway to alleviate pulmonary hypertension in mice.
- | Journal: Activation of mitochondrial aldehyde dehydrogenase 2 promotes hair growth in human hair follicles. (Pubmed Central) - Sep 25, 2024
signaling pathway to alleviate pulmonary hypertension in mice. Our findings highlight the hair growth promotion effects of ALDH2 activation in HFs and its potential as a promising therapeutic approach for promoting anagen induction.
- Endogenous Acrolein Scavenging as a Novel Neuroprotective Strategy After Spinal Cord Injury (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_1964;
This study has further demonstrated acrolein as a critical player in the pathogenesis of SCI, as well as an effective therapeutic target to enhance recovery in SCI. Furthermore, our data also supports the role of ALDH2 as a potential target for potentiating endogenous anti-acrolein capability through pharmaceutical intervention in SCI and other neurotrauma and degenerative diseases where acrolein is known to play a role.
- | bleomycin / Generic mfg.
Journal: ALDH2 Deficiency Aggravates Lung Fibrosis through Mitochondrial Dysfunction and Aging in Fibroblasts. (Pubmed Central) - Jul 28, 2024
A decrease in ALDH2 expression was observed in patients with idiopathic pulmonary fibrosis and bleomycin-treated mice...In conclusions, ALDH2 expression inhibits the pathogenesis of pulmonary fibrosis. Strategies to upregulate or activate ALDH2 expression could be potential therapies for pulmonary fibrosis.
- morphine sulphate / Generic mfg.
Mitochondrial Aldehyde Dehydrogenase-2 Regulates Morphine-Induced Peripheral Neuroinflammation (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_2180;
Alda-1 prevents OIH and neuroinflammation by reducing 4-HNE. Therefore, ALDH2 activators may be potential therapeutic molecules to control morphine adverse effects.
- |||| FP-045 / Foresee Pharma
New P2 trial: WINDWARD: Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (clinicaltrials.gov) - Jun 25, 2024
P2, N=126, Not yet recruiting, Sponsor: Foresee Pharmaceuticals Co., Ltd.
- | Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Journal: Mitochondrial aldehyde dehydrogenase rescues against diabetic cardiomyopathy through GSK3?-mediated preservation of Mitochondrial integrity and parkin-mediated mitophagy. (Pubmed Central) - Jun 22, 2024
Our data discerned a vital role for ALDH2 in diabetic cardiomyopathy possibly through regulation of Akt, GSK3? activation, parkin mitophagy and mitochondrial function.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Mitochondrial ALDH2 improves (Pubmed Central) - Jun 1, 2024
Mitochondrial ALDH2 activation could inhibit the progression of doxorubicin induced pancreatic ?-cell dysfunction by inhibiting the acid sphingomyelinase induction of ceramide, by regulating the activation of CK2 signaling. Our research lays the foundation of ALDH2 activation as a therapeutic target for the precise treatment of chemotherapy drug induced ?-cell dysfunction.
- FP-045 / Foresee Pharma
A Multinational Phase 2, Randomized, Double-blinded, Placebo-controlled, Multiple-dose Study to Evaluate the Safety and Efficacy of FP-045, An Aldehyde Dehydrogenase 2 Activator in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (San Diego Convention Center, Area L (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_957;
The change from baseline to week-12 in the SF-36v2-Health Survey, the Walking Impairment Questionnaire-(WIQ), and patient-reported-outcome measures-(PROM) as CAMPHOR-(or PAH-SYMPACT). Conclusion The WINDWARD Phase-2 Study aims to investigate the potential of FP-045 therapy as a first-in-class small molecule with a novel mechanism of action for patients with PH-ILD.
- | Journal: Mitochondrial aldehyde dehydrogenase-2 coordinates the hydrogen sulfide - AMPK axis to attenuate high glucose-induced pancreatic ?-cell dysfunction by glutathione antioxidant system. (Pubmed Central) - Jan 22, 2024
Furthermore, treatment with NaHS, an HS donor, selectively preserves ?-cell function by promoting ALDH2 activity, leading to the inhibition of lipid peroxidation by high-glucose concentrations. Collectively, our results provide the first direct evidence that ALDH2 activation enhances HS-AMPK-G6PD signaling, leading to improved ?-cell function and survival under high-glucose conditions via the glutathione redox balance.
- | Journal: Aldehyde dehydrogenase 2 preserves mitochondrial function in the ischemic heart: a redox-dependent mechanism for AMPK activation by thioredoxin-1. (Pubmed Central) - Jan 8, 2024
ALDH2 alleviates myocardial injury via increased mitochondrial biogenesis and reduced oxidative stress, and these effects were achieved via Trx1-mediating AMPK-PGC1-? signaling activation.
- | Journal, IO biomarker: ALDH2 mitigates LPS-induced cardiac dysfunction, inflammation, and apoptosis through the cGAS/STING pathway. (Pubmed Central) - Dec 25, 2023
We demonstrated that ALDH2 alleviated LPS-induced cardiac dysfunction, inflammation, and apoptosis through the cGAS/STING signaling pathway, thereby protecting against LPS-induced cardiac injury. This study identifies a novel therapeutic approach for treating sepsis-induced cardiomyopathy (SIC).
- | ketoconazole / Generic mfg.
Journal: Role of covalent modification by hepatic aldehydes in dictamnine-induced liver injury. (Pubmed Central) - Dec 21, 2023
Inhibition of the bioactivation by CYP3A inhibitor ketoconazole prevented the protein adduction...Application of aldehyde dehydrogenase-2 activator ALDA-1 or nucleophilic trapping reagent N-acetyl-L-lysine significantly reduced the protein adduction and attenuated dictamnine-induced liver injury without affecting the bioactivation. In conclusion, the metabolic activation of the furan ring of dictamnine resulted in the protein adduction by multiple hepatic aldehydes and the protein modification played a crucial role in dictamnine-induced liver injury.
- | AD-9308 / Foresee Pharma
Journal: 4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification. (Pubmed Central) - Nov 22, 2023
4-HNE inhibition of Dicer directly impairs miRNA biogenesis in heart failure. Strikingly, decreasing cardiac 4-HNE levels through pharmacological ALDH2 activation is sufficient to re-establish Dicer activity and miRNA biogenesis; thereby representing potential treatment for patients with heart failure.
- Alda-1, an ALDH2 activator, exerts anti-neuroinflammatory effect in Alzheimer's disease. (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_5943;
Our results showed that pretreatment of Alda-1 attenuated mutant TOMM40-induced mitochondrial ROS generation in BV2 microglial cells. Alda-1 could be used for preventing and treating AD by targeting microglial mitochondria.
- | AD-9308 / Foresee Pharma
Journal: A common East-Asian ALDH2 mutation causes metabolic disorders and the therapeutic effect of ALDH2 activators. (Pubmed Central) - Oct 4, 2023
AD-9308 treatment ameliorates diet-induced obesity and fatty liver, and improves glucose homeostasis in both male Aldh2 wild-type and knock-in mice. Our data highlight the therapeutic potential of reducing toxic aldehyde levels by activating ALDH2 for metabolic diseases.
- | Journal, IO biomarker: ALDH2 activation attenuates oxygen-glucose deprivation/reoxygenation-induced cell apoptosis, pyroptosis, ferroptosis and autophagy. (Pubmed Central) - Sep 22, 2023
Our data highlight the therapeutic potential of reducing toxic aldehyde levels by activating ALDH2 for metabolic diseases. Collectively, our results implied that ALDH2 attenuated OGD/R-induced cell apoptosis, pyroptosis, ferroptosis and autophagy to promote cell viability in HT22 cells and mouse cortical neurons.
- | Preclinical, Journal: Activation of aldehyde dehydrogenase-2 improves ischemic random skin flap survival in rats. (Pubmed Central) - Jul 17, 2023
ALDH2 activation can effectively enhance random skin flap viability via inhibiting PINK1/Parkin-dependent mitophagy. Moreover, enhancement of ALDH2 activity also exerts anti-inflammatory and angiogenic properties.
- | erastin - Whitehead Institute for Biomedical Research, Dana / Farber Cancer Institute, Columbia University, Prolexys
Journal: ALDH2 ameliorates ethanol-induced gastric ulcer through suppressing NLPR3 inflammasome activation and ferroptosis. (Pubmed Central) - Jul 7, 2023
Also, the suppressive role of ALDH2 in inflammatory response and oxidative stress was reversed by ferroptosis activator erastin or NLRP3 activator nigericin in HCl/ethanol-challenged GES-1?cells. To be summarized, ALDH2 might play the protective role in the process of GU.
- | Journal: Acetaldehyde dehydrogenase 2 activation attenuates sepsis-induced brain injury through NLRP3 inflammasome regulation. (Pubmed Central) - Feb 27, 2023
The activation of ALDH2 can attenuate sepsis-induced brain injury, hypothetically through regulation of the NLRP3/caspase-1 signaling pathway. Therefore, ALDH2 could potentially be considered as a new therapeutic target for the treatment of sepsis-induced brain injury.
- | Preclinical, Journal: ALDH2 deficiency increases susceptibility to binge alcohol-induced gut leakiness, endotoxemia, and acute liver injury in mice through the gut-liver axis. (Pubmed Central) - Dec 19, 2022
Furthermore, CRISPR/Cas9-mediated knockout of ALDH2 in T84 cells increased alcohol-mediated cell damage and paracellular permeability. All these findings demonstrate the critical role of ALDH2 in alcohol-induced epithelial barrier dysfunction and suggest that ALDH2 deficiency or gene mutation in humans is a risk factor for alcohol-mediated gut and liver injury, and that ALDH2 could be an important therapeutic target against alcohol-associated tissue or organ damage.
- Endogenous Acrolein Scavenging as a Novel Neuroprotective StrategyAfter Spinal Cord Injury (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_11306;
This study has further demonstrated the critical role of acrolein in the pathogenesis of SCI, but also the therapeutic value of suppressing acrolein in SCI. Furthermore, our data also supports a role of ALDH2 as a potential target for anti-acrolein pharmaceutical intervention in neurotrauma diseases.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Preclinical, Journal: Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF. (Pubmed Central) - Oct 1, 2022
This combination was even more effective than EMP alone. Our data indicate that ALDH2 activation along with the treatment of hypoglycemic agents may be a salient strategy to alleviate diabetes-associated HFpEF.
- Aldehyde Dehydrogenase 2 Agonist Reverses Fibroblast Activation in the End Stage Human Right Ventricle Failure via 3’Utr Regulation of Profibrotic Genes (N231) - Sep 18, 2022 - Abstract #AHA2022AHA_6839;
In RVF, fibroblasts express mRNA of profibrotic genes with shortened 3'UTRs, suggesting the feasibility of developing antifibrotic therapies targeting 3'UTRs in myofibroblasts. Furthermore, our findings suggest that Alda-1 has a therapeutic role in mitigating cardiac fibrosis in RVF hearts by attenuating 4HNE-mediated dysregulation of APA.
- | Journal: Aldehyde dehydrogenase 2 and arrhythmogenesis. (Pubmed Central) - Sep 10, 2022
In this review, we summarize recent researches on the potential roles of ALDH2 activation and antiarrhythmic protection, as well as the role played by the ALDH2*2 polymorphism (rs671) in promoting arrhythmic risk. Additionally, we discuss important new findings illustrating the use of ALDH2 activators, which may prove to be promising antiarrhythmic therapy agents.
- | Journal: Identification and Functional Evaluation of Polyphenols That Induce Regulatory T Cells. (Pubmed Central) - Jul 29, 2022
Oral administration of quercetin and luteolin increased IgA production in feces of mice. Therefore, quercetin and luteolin can induce Tregs via RALDH2 activation and consequently increase IgA production, suggesting that they can enhance intestinal barrier function.
- | disulfiram / Generic mfg.
Journal: Aldehyde dehydrogenase 2 augments adiponectin signaling in coronary angiogenesis in HFpEF associated with diabetes. (Pubmed Central) - Jul 12, 2022
Treatment with disulfiram, an ALDH2 inhibitor, exacerbated 4HNE-mediated decreases in APN-induced increased coronary angiogenesis and APN-signaling cascades, whereas pretreatment with alda1, an ALDH2 activator, rescued the effect of 4HNE...Alda1 treatment improved APN-mediated angiogenesis in AF and db/db mice. In summary, 4HNE-induces APN resistance and a subsequent decrease in coronary angiogenesis in diabetic mouse heart which was rescued by ALDH2.
- | disulfiram / Generic mfg.
Journal: Exposure to the Dioxin-like Pollutant PCB 126 Afflicts Coronary Endothelial Cells via Increasing 4-Hydroxy-2 Nonenal: A Role for Aldehyde Dehydrogenase 2. (Pubmed Central) - Jun 24, 2022
However, pretreatment with 2.5 µM disulfiram (DSF), an ALDH2 inhibitor, or 10 µM Alda 1, an ALDH2 activator, before the PCB 126 challenge exacerbated and rescued the PCB 126-mediated decrease in coronary angiogenesis by modulating the 4HNE adduct levels respectively. Finally, we conclude that ALDH2 can be a therapeutic target to alleviate environmental pollutant-induced CMDs.
- disulfiram / Generic mfg.
Aldehyde Dehydrogenase 2 Augments Adiponectin Signaling In Coronary Angiogenesis In Hfpef Associated With Diabetes (Salon B, Lower Level) - Jun 18, 2022 - Abstract #BCVS2022BCVS_366;
Treatment with disulfiram (DSF), an ALDH2 inhibitor, exacerbated 4HNE-mediated decreases in APN-induced increased coronary angiogenesis and APN-signaling cascades, whereas pretreatment with alda1, an ALDH2 activator, rescued the effect of 4HNE...Alda-1 treatment improved APN-mediated angiogenesis significantly in db/db and AF mice. In conclusion, 4HNE-induces APN resistance and subsequently decreases coronary angiogenesis in diabetic HFpEF which was rescued by ALDH2 activation.
- | Preclinical, Journal: Crosstalk of pyroptosis, ferroptosis, and mitochondrial aldehyde dehydrogenase 2-related mechanisms in sepsis-induced lung injury in a mouse model. (Pubmed Central) - Apr 9, 2022
In conclusion, both pyroptosis and ferroptosis participate in CLP-induced ALI, and ALDH2 plays a protective role by reducing pyroptosis and ferroptosis. This study provides a scientific basis for the treatment of lung injury in sepsis.
- | Journal: Alda-1, an Activator of ALDH2, Improves Postresuscitation Cardiac and Neurological Outcomes by Inhibiting Pyroptosis in Swine. (Pubmed Central) - Apr 1, 2022
Moreover, the severity of oxidative stress indicated by the changes of 4-hydroxy-2-nonenal and malondialdehyde was significantly decreased in the heart and brain in all animals treated with Alda-1 compared to the CPR group. Thus, Alda-1 mitigated postresuscitation cardiac and neurological dysfunction and injuries possibly by inhibiting oxidative stress-mediated NLRP3 inflammasome activation and pyroptosis in a swine model of CA and resuscitation.
- | Journal: Aldehyde dehydrogenase 2 protects against acute kidney injury by regulating autophagy via Beclin-1 pathway. (Pubmed Central) - Feb 26, 2022
In mice with AKI induced by renal ischemia ischemia/reperfusion, ALDH2 overexpression or pretreatment regulated autophagy mitigating apoptosis of RTECs and renal injury. Our data collectively substantiate a critical role of ALDH2 in AKI via autophagy activation involving the Beclin-1 pathway.
- | Journal: Activation of Aldehyde Dehydrogenase 2 Ameliorates Glucolipotoxicity of Pancreatic Beta Cells. (Pubmed Central) - Jan 13, 2022
However, the above effects of Alda-1 were abolished in Aldh2 knockdown MIN6 cells. In conclusion, we reported that the activator of ALDH2 not only enhanced GSIS, but also ameliorated the glucolipotoxicity of beta cells by reducing both the mitochondrial and intracellular ROS levels, thereby improving mitochondrial function, restoring beta cell function, and protecting beta cells from apoptosis and death.
- | Preclinical, Journal: Diabetic Aldehyde Dehydrogenase 2 Mutant (ALDH2*2) Mice Are More Susceptible to Cardiac Ischemic-Reperfusion Injury Due to 4-Hydroxy-2-Nonenal Induced Coronary Endothelial Cell Damage. (Pubmed Central) - Jan 7, 2022
Systemic pretreatment with Alda-1 (10 mg/kg per day), an activator of both ALDH2 and ALDH2*2, led to a reduction in myocardial infarct size and dysfunction, and coronary perfusion pressure upon cardiac IRI by increasing CEC population and coronary arteriole opening. Conclusions Low ALDH2 activity exacerbates 4HNE-mediated CEC injury and thereby cardiac dysfunction in diabetic mouse hearts subjected to IRI, which can be reversed by ALDH2 activation.
- | Journal: Pharmacological Activation Of Aldehyde Dehydrogenase 2 Protects Against Heatstroke-Induced Acute Lung Injury by Modulating Oxidative Stress and Endothelial Dysfunction. (Pubmed Central) - Jan 6, 2022
Here, we demonstrated the crucial roles of ALDH2 in protecting against heat stress-induced ROS production and vascular inflammation and preserving the viability of ECs. The activation of ALDH2 by Alda-1 attenuates WBH-induced ALI in vivo.
- | S-nitrosothiol (N6022) / Alpine Immune Sci
Journal: GSNOR and ALDH2 alleviate traumatic spinal cord injury. (Pubmed Central) - Jan 4, 2022
Combining the specific inhibitor of GSNOR (N6022) with the selective activator of ALDH2 (Alda-1) provides greater protection to the neurovascular unit and confers greater functional recovery. The study is novel, and the combination therapy (N6022+Alda-1) possesses translational potential.
- | Preclinical, Journal: Critical role of mitochondrial aldehyde dehydrogenase 2 in acrolein sequestering in rat spinal cord injury. (Pubmed Central) - Dec 20, 2021
All animal work was approved by Purdue Animal Care and Use Committee (approval No. 1111000095) on January 1, 2021.
- | Journal: Magnolol, a natural aldehyde dehydrogenase-2 agonist, inhibits the proliferation and collagen synthesis of cardiac fibroblasts. (Pubmed Central) - Nov 4, 2021
Mag could enhance the activity of recombinant human ALDH2 proteins with a half-maximal effective concentration of 5.79 × 10 M. In addition, ALDH2 activation via Alda-1 inhibited cardiac fibroblast proliferation and collagen synthesis, while ALDH2 inhibition via daidzin partially blocked the suppressive effects of Mag. In summary, Mag may act as a natural ALDH2 agonist and inhibit cardiac fibroblast proliferation and collagen synthesis.
- | Preclinical, Journal, IO biomarker: Impact of mitochondrial aldehyde dehydrogenase 2 on cognitive impairment in the AD model mouse. (Pubmed Central) - Aug 7, 2021
Taken together, ALDH2 overexpression significantly improves the cognitive function of the AD mice. Furthermore, our results suggested that ALDH2 protects against Aβ hippocampal neuronal toxicity possibly through alleviating toxic aldehydes and ROS, as well as increasing ATP production to preserve mitochondrial integrity and reduce neuronal apoptosis.
- | disulfiram / Generic mfg.
Journal: A role for aldehyde dehydrogenase (ALDH) 2 in angiotensin II-mediated decrease in angiogenesis of coronary endothelial cells. (Pubmed Central) - Jul 31, 2021
In summary, ALDH2 can be an important target in reducing 4HNE-induced proteotoxicity and improving angiogenesis in MCECs. Finally, we conclude ALDH2 activation can be a therapeutic strategy to improve coronary angiogenesis to ameliorate cardiometabolic diseases.
- [VIRTUAL] Mitochondrial Aldehyde-Dehydrogenase-2 And Protein Kinase C? Are Involved In Aldehyde-Induced Pain In Mice () - Jun 29, 2021 - Abstract #IASP2021IASP_658;
activation may contribute to both nociception and antinociception with the downstream mitochondrial ALDH2 activation as a key pathway for pain control. The development of new strategies to better understand the mechanisms involved in 4-HNE signaling may open new perspectives for pain management.
- [VIRTUAL] Aldehyde Dehydrogenase-2 Inhibition Heightens Neuropathic Pain () - Jun 29, 2021 - Abstract #IASP2021IASP_654;
ALDH2 activation with Alda-1 prevents CCI-induced increase in the aldehydic load without interfering wiith the H2O2 levels. Therefore, ALDH2 is a key enzyme that regulates neuropathic pain development.
- | Preclinical, Journal: Neuroprotective effects of Alda-1 mitigate spinal cord injury in mice: involvement of Alda-1-induced ALDH2 activation-mediated suppression of reactive aldehyde mechanisms. (Pubmed Central) - Jun 9, 2021
Consequently, we suggest that Alda-1 may have therapeutic potential for the treatment of human SCI. Animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of MUSC (IACUC-2019-00864) on December 21, 2019.
- | Journal: Aldehyde Dehydrogenase 2 Protects Against Lipopolysaccharide-Induced Myocardial Injury by Suppressing Mitophagy. (Pubmed Central) - May 25, 2021
Conversely, ALDH2 inhibition promoted the expression of LC3B by increasing 4-hydroxy-trans-2-nonenal accumulation. Consequently, ALDH2 may protect the heart from lipopolysaccharide-induced injury by suppressing PINK1/Parkin-dependent mitophagy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Effect of doxorubicin on cardiac lipid metabolism-related transcriptome and the protective activity of Alda-1. (Pubmed Central) - May 20, 2021
Alda-1 administration promoted reduction in the severity of the histopathological injuries (after single dose of DOX) and Slc27a2 overexpression was restored. In conclusion, the study revealed novel insights regarding the development of DOX-mediated cardiomyopathy, indicating a relationship between DOX exposure and FABP4 and Slc27a2 overexpression, and confirmed the cardioprotective effect of Alda-1.
- || disulfiram / Generic mfg.
Review, Journal: A critical assessment of the potential of pharmacological modulation of aldehyde dehydrogenases to treat the diseases of bone loss. (Pubmed Central) - May 15, 2021
ALDH2 inhibition by disulfiram (DSF) and activation by alda-1 cause reduction and induction of bone formation, respectively...The scope of structure-activity based studies with ALDH2 and the alda-1-like molecule could lead to the discovery of novel osteoanabolic molecules. This review will critically discuss the molecular mechanism of the ethanol and its principal metabolite, acetaldehyde in the context of ALDH2 in bone cells, and skeletal homeostasis.
- | Preclinical, Journal: Pretreatment with the ALDH2 activator Alda‑1 protects rat livers from ischemia/reperfusion injury by inducing autophagy. (Pubmed Central) - Apr 27, 2021
Alda‑1 may confer this protection by inducing autophagy through the AKT/mTOR and AMPK signaling pathways. Therefore, ALDH2 could represent a potential pharmacological target in the clinical treatment of HIRI.
- | Journal: The discovery of novel small molecule allosteric activators of aldehyde dehydrogenase 2. (Pubmed Central) - Apr 24, 2021
It has good activity in vitro and in vivo, which could reduce infarct size by ∼70% in ischemic stroke rat models. This study provided good lead compounds for the further development of ALDH2 activators.
- | Preclinical, Journal: A Novel ALDH2 Activator AD-9308 Improves Diastolic and Systolic Myocardial Functions in Streptozotocin-Induced Diabetic Mice. (Pubmed Central) - Apr 7, 2021
In conclusion, ADLH2 activation effectively ameliorated diabetic cardiomyopathy, which may be mediated through detoxification of 4-HNE. Our findings highlighted the therapeutic potential of ALDH2 activation for treating diabetic cardiomyopathy.
- | Journal: Aldehyde dehydrogenase 2 protects against sympathetic excitation-induced cardiac fibrosis. (Pubmed Central) - Mar 26, 2021
In addition, wild-type mice treated with Alda-1 manifested with reduced fibrosis and better cardiac function after ISO pump. In summary, Alda-1 alleviates sympathetic excitation-induced cardiac fibrosis via decreasing mitochondrial ROS accumulation, highlighting ALDH2 activity as a promising drug target of cardiac fibrosis.